Skip to main content

Table 1 Summary table of analysis populations for selected autoantibodies and outcomes

From: Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Biomarker Baseline requirement Placebo (N = 105) Baricitinib 2 mg (N = 105) Baricitinib 4 mg (N = 104)
Anti-dsDNA ≥30 IU/mL 51 (48.6) 56 (53.3) 53 (51.0)
IgG No requirement 101 (96.2) 99 (94.3) 96 (92.3)
C3 <90 mg/dL 30 (28.6) 30 (28.6) 34 (32.7)
C4 <10 mg/dL 15 (14.3) 26 (24.8) 15 (14.4)
Anti-Sm ≥30 IU/mL 12 (11.47) 7 (6.67) 9 (8.7)
aCL IgM >12 MPL 20 (19.0) 22 (20.9) 22 (21.2)
aCL IgG >14 GPL 10 (9.5) 10 (9.5) 5 (4.8)
aCL IgA >11 APL 4 (3.8) 6 (5.7) 1 (1.0)
Anti-RNP ≥30 IU/mL 28 (26.7) 21 (20.0) 28 (27.0)
Anti-SSA >20 IU/mL 35 (33.3) 27 (25.7) 27 (26.0)
Anti-SSB >20 IU/mL 15 (14.3) 15 (14.3) 16 (15.3)
  1. Values are N-observed (N-observed % of N)
  2. APL/GPL/MPL arbitrary units for IgA, IgG, and IgM isotypes, respectively, C component, dsDNA double-stranded deoxyribonucleic acid, Ig immunoglobulin, Sm Smith, RNP ribonucleoproteins, SS Sjögren’s syndrome-related antigen, IU international unit